Xlife Sciences AG: Successful Capital Raising of Six Million Swiss Francs
Capital increase of Xlife Sciences AG
Successful capital raising of six million Swiss francs
Xlife Sciences AG has successfully closed its capital increase and raised a total of 6.02 million Swiss Francs of new capital as of December 3, 2020. The placement was oversubscribed at the end of the subscription period. The management of the company sees the strong demand as a confirmation for its business model. The capital will be used almost exclusively for existing and new projects.
In the capital round completed on December 3, 2020, existing and new investors subscribed for shares with a total value of CHF 6.02 million. For Oliver R. Baumann, CEO of Xlife Sciences AG, the high demand of investors is a confirmation of the successful business model. "The strong interest of investors shows that our company, with its strategy of holding and developing a broad portfolio of early-stage life science projects is an attractive investment even in challenging times such as the corona crisis". Investors who are already invested in the life sciences sector consider the business model of Xlife as an attractive investment stage diversification, Baumann continues.
Capital to expand the project portfolio
According to the management of Xlife Sciences AG, the fresh capital will be used almost exclusively for the further development of the project portfolio. The fixed costs of the company as management company should be maintained as low as possible. Yesterday, it was already announced that Xlife's portfolio will grow by two projects with Panmabs GmbH and Xarma Life Science GmbH, both based in Mainz.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
|
Language: |
English |
|
Company: |
Xlife Sciences AG |
|
|
Klausstrasse 19 |
|
|
8008 Zürich |
|
|
Switzerland |
|
Phone: |
0041 44 385 84 60 |
|
E-mail: |
|
|
Internet: |
|
|
ISIN: |
CH0461929603 |
|
WKN: |
A2PK6Z |
|
Listed: |
Regulated Unofficial Market in Frankfurt, Munich |
|
EQS News ID: |
1152688 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201203006171/en/
Contact information
For media inquiries:
Oliver R. Baumann, CEO Xlife Sciences AG
Tel. +41 44 385 84 60
oliver.baumann@xlifesciences.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ubigi Voted Most Reliable eSIM for Mobile Professionals According to Latency Report 20251.12.2025 17:13:00 EET | Press release
Ubigi, a pioneer in eSIM solutions for travellers and connected professionals, has been ranked number one worldwide for connection quality according to the Latency Report 2025. This independent study evaluates eSIMs based on three key criteria: latency, jitter and packet loss. Thanks to its cutting-edge international network infrastructure, Ubigi has established itself as the benchmark for reliability for mobile professionals. Its architecture is based on seven Packet Gateways (P-GWs) spread across Europe, Asia and the Americas, allowing data to transit through the Internet point closest to the user. The result: latency reduced by a factor of two to five depending on the area and optimal stability for video conferencing, VPN and cloud services. Ubigi's performance, validated by the Latency Report 2025, stands out: Average latency: 35 ms in Europe, 92 ms in Asia; Jitter: only 5 ms; Packet loss: < 0.2%, one of the best reliability ratings measured. These results, confirmed by tests in Li
Andersen Consulting Enhances Platform with Peers Technology + Consulting1.12.2025 16:30:00 EET | Press release
Andersen Consulting adds collaborating firm Peers Consulting + Technology, a Brazilian firm known for accelerating strategic change through digital innovation and advanced analytics. Founded in 2012, Peers delivers end-to-end services that combine strategic insight with digital execution. Its offerings span advanced analytics and generative AI, IT strategy, customer experience, finance, cybersecurity, sustainability, supply chain, M&A, and organizational transformation. Recognized for its impact across Latin America, Peers equips clients to modernize operations, enhance decision-making, and drive sustainable performance. “We believe meaningful transformation happens at the intersection of data, technology, and human insight,” said Managing Partner Pedro Ribeiro. “We work side by side with our clients to turn challenges into growth. Collaborating with Andersen Consulting enables us to extend that approach globally and help more organizations navigate complexity with clarity and speed.”
Rimini Street Announces Additional Stock Repurchase Transactions1.12.2025 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the following: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201195169/en/ Rimini Street Announces Additional Stock Repurchase Transactions Share Repurchases The Company repurchased a total of 975,000 shares of common stock to date in the fourth fiscal quarter of 2025, for approximately $3.8 million with an average per share purchase price of $3.92, reducing outstanding shares by approximately 1.1%1. The Company has now completed and announced $13.3 million in common stock repurchases under its $50 million Common Stock Repurchase Plan that was approved by the Rimini Street Board of Directors in February 2022 and recently extended through June 2029. $7.6 million of common stock repurchase
MVNO Europe - Europe's Competitiveness Depends on a Truly Open Telecoms Market, Not on Increased Concentration That Benefits a Handful of Mobile Operators1.12.2025 15:37:00 EET | Press release
This is the warning that MVNO Europe – through its President Jacques Bonifay – has issued to the European Commission in an open letter to Ursula von der Leyen and Vice-President Henna Virkkunen. As discussions on the Digital Networks Act (DNA) enter their decisive phase, the association, which brings together alternative mobile operators in Europe, points out that the EU's digital ambition can only be achieved if competition remains a structuring principle, not an adjustment variable. While some players are calling for "necessary" consolidation in the sector, MVNO Europe warns against a simplistic and economically dangerous vision. "Reducing the number of operators has never guaranteed innovation, access for European industries, or fair conditions for new digital services. On the contrary, the historical driver of European competitiveness has always been the diversity of players, models, technologies and services," says Jacques Bonifay, President of MVNO Europe and CEO of Transatel. Re
IonQ and CCRM Announce Strategic Quantum-Biotech Collaboration to Accelerate Development of Advanced Therapeutics1.12.2025 14:30:00 EET | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an investment partnership with the Centre for Commercialization of Regenerative Medicine (CCRM) to accelerate next-generation therapeutic development using hybrid quantum and quantum-AI technologies. The partnership includes an investment commitment into CCRM’s new quantum-biotech initiatives and establishes IonQ as the core technology partner across CCRM’s global network of advanced therapy hubs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201706303/en/ IonQ serves as strategic quantum technology partner across CCRM’s leading global regenerative medicine network. With more than 100,000 square feet of good manufacturing practice (GMP) facilities, 300+ scientific staff and a global network of academic and industry partners, CCRM is one of the world’s leading accelerators for advanced therapies. CCRM was established in 2011 in Toronto, Canada, to rea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom